Binder G, Ranke M B
University Children's Hospital, Tübingen, Germany.
J Clin Endocrinol Metab. 1995 Apr;80(4):1247-52. doi: 10.1210/jcem.80.4.7714096.
We screened 10 children with sporadic severe isolated GH deficiency (IGHD) for GH-1 gene splice site mutations using ectopic transcript analysis. None had a history of birth trauma, congenital defects, thyroid disorders, or PRL deficiency. The mean age of these patients at diagnosis was 3.5 yr; the mean height at diagnosis was -4.0 SD score. GH-1 gene deletion was excluded in all cases. Ribonucleic acid (RNA) from lymphocytes was reverse transcribed and amplified by nested polymerase chain reaction, using two primer pairs with annealing sites within exons 2 and 5 of the GH-1 gene. The main polymerase chain reaction fragment obtained was 460 basepairs and proved to be the amplification of the GH-1 transcript. We also found three shorter fragments which were alternatively spliced GH-1 transcripts, including a variant devoid of the first 45 basepairs of exon 3, a second lacking the whole exon 3, and a third one, not previously described, lacking both exon 3 and exon 4. We found the same pattern of alternative splicing in RNA from GH-producing pituitary tumor tissue, which served as a positive control. In 1 of 10 patients, a pathologically shortened main fragment lacking exon 3 was detected. As proved by sequencing genomic DNA, this was the result of a heterozygous splice site mutation, with transversion from G to C of the first base of the donor splice site of intron III generating a new DdeI recognition site. The other allele had no mutation. DdeI digestion enabled us to rule out the defect in the parents' DNA. Thus, the mutation was de novo. As the patient with the mutation displayed the most severe and earliest growth retardation in the study group and had virtually no GH in serum, it must be assumed that the heterozygous genetic defect resulted in a dominant negative effect. The reason for this is still unclear. Recently, within a family that exhibited the autosomal dominant phenotype of IGHD (IGHD-II), a heterozygous point mutation was located 5 bases down-stream from that we describe here. A similar effect on splicing was observed. In conclusion, analysis of ectopic GH-1 transcripts enabled us to detect 1) a new alternatively spliced GH-1 messenger RNA variant lacking exons 3 and 4, and 2) 1 of 10 sporadic cases of severe idiopathic IGHD due to a heterozygous de novo splice site mutation in the GH-1 gene that changes G to C in the first base of intron III.(ABSTRACT TRUNCATED AT 400 WORDS)
我们采用异位转录本分析方法,对10例散发型严重孤立性生长激素缺乏症(IGHD)患儿进行生长激素-1(GH-1)基因剪接位点突变筛查。这些患儿均无出生时产伤、先天性缺陷、甲状腺疾病或泌乳素缺乏病史。这些患者诊断时的平均年龄为3.5岁;诊断时的平均身高标准差评分为-4.0。所有病例均排除了GH-1基因缺失。利用两对分别与GH-1基因外显子2和5内退火位点结合的引物,对淋巴细胞中的核糖核酸(RNA)进行逆转录并通过巢式聚合酶链反应进行扩增。获得的主要聚合酶链反应片段为460个碱基对,经证实是GH-1转录本的扩增产物。我们还发现了三个较短的片段,它们是GH-1转录本的可变剪接产物,其中一个变体缺失外显子3的前45个碱基对,第二个缺失整个外显子3,第三个此前未被描述,缺失外显子3和外显子4。我们在作为阳性对照的产生生长激素的垂体肿瘤组织的RNA中发现了相同的可变剪接模式。在10例患者中的1例中,检测到一个病理上缩短的、缺失外显子3的主要片段。经基因组DNA测序证实,这是一个杂合剪接位点突变的结果,内含子III供体剪接位点的第一个碱基由G颠换为C,产生了一个新的DdeI识别位点。另一个等位基因无突变。DdeI酶切使我们能够排除父母DNA中的缺陷。因此,该突变是新发的。由于该突变患者在研究组中表现出最严重和最早的生长发育迟缓,且血清中几乎没有生长激素,因此必须假定该杂合基因缺陷产生了显性负效应。其原因尚不清楚。最近,在一个表现出IGHD常染色体显性表型(IGHD-II)的家族中,发现了一个杂合点突变,位于我们这里描述的位点下游5个碱基处。观察到了对剪接的类似影响。总之,对异位GH-1转录本的分析使我们能够检测到:1)一种新的缺失外显子3和4的可变剪接的GH-1信使RNA变体;2)10例散发型严重特发性IGHD病例中的1例,该病例是由于GH-1基因中一个杂合新发剪接位点突变导致内含子III的第一个碱基由G变为C。(摘要截短至400字)